Aarti Industries Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qiyexjentdh1y4fh8kjwuyuf.pdf

Key Takeaways


Zone IV: Commissioning, Ramp-Up & Financial Trajectory

Suyog Kotecha: "The good news is that whatever we have commissioned in Zone IV, it has achieved the ramp-up, the scale, both in terms of efficiency norms and the capacity norms in a relatively short span of time. So we have been able to do first time right across many of these capacities."

Energy Portfolio: The Quarter's Swing Factor


New Long-Term Contract & Partnership Model

Suyog Kotecha: "We have seen very good traction when it comes to inbound inquiries to do long-term partnerships for specialty chemical manufacturing in India to serve markets in Europe, in Japan, in U.S. That inquiry flow has gone up, and we are in active conversation with some of these customers."

Margin Mechanics: The Inflation Pass-Through Story

Suyog Kotecha: "Tere is definitely an upside in the NCB chain that we are seeing compared to our assumption."

Chain-by-Chain Performance & Outlook

Suyog Kotecha: "Te biggest lever for there was China's anti-involution strategy, which impacted NCB chain, right, where we removed the VAT subsidy rebates that Chinese players used to get, which was as high as 13% of the product price and if something similar happens like that in PDA chain, of course, the turnaround will be pretty dramatic."

Balance Sheet, Capex & Strategic Priorities

Suyog Kotecha: "Watever best we can get in brownfield and debottlenecking versions is what we are trying to get done quickly and accrue to the bottom line."

Guidance & Commitments

ComitmentSpecificsTimline
PDA chain traction resumptionTraction to resume, underpinned by accelerating DCB demandQ3 FY27
Zone IV product rollout5 to 10 products in FY27, expanding to 20–25 products across 5 chemistry blocks by FY28; remaining 4 chemistry blocks online within FY27FY27–FY28
Zone IV bottom-line contribution₹250 crore to ₹350-odd crore in first 18 months; aspiration to be EBITDA additive in FY28FY28
Zone IV capitalization~₹1,800–1,900 crore of CWIP capitalizedBy March 31, 2027
New long-term contract commercial operationsDedicated facility operational, revenue potential ~₹1,500 croreFY29
Fund-raise executionUp to ₹1,000 crore to deleverage balance sheetPost-EGM approval (Oct 31, 2026)
Energy feedstock strategic initiativesImplementation of initiatives from partnerships to own manufacturingNext 3–4 months
Energy portfolio shareSettle between 30% to 40% of overall portfolioMidterm
Cost and efficiency leversImpact increasingly visible in bottom lineGoing forward
FY28 EBITDA trajectoryThree levers (cost efficiency, operating leverage, capex ramp-up) provide line of sight to guided rangeFY28

Key Metrics

MetricQ2 FY27
Revenue₹3,887 cr, up 73% YoY
EBITDA₹418 cr, up 44% YoY; highest-ever quarterly EBITDA
H1 FY27 EBITDAOver ₹802 cr, up over 58% YoY from ₹507 cr in H1 FY26
PAT₹169 cr, up ~60% YoY
H1 FY27 PAT₹324 cr, up 117% YoY from ₹149 cr in H1 FY26
Net debtOver ₹4,650 cr
FY27 capex plan₹700 cr to ₹800 cr
FY28 EBITDA target₹1,800 cr to ₹2,200 cr
Energy segment share of portfolio50% of total portfolio in Q2; midterm expectation 30% to 40%
Fuel Additives capacity360 KTPA, expanded from 290 KTPA in Q1 FY27
DCB capacity140 KTPA, post-debottlenecking
Zone IV CWIP₹1,800 cr to ₹1,900 cr, expected capitalized by March 31, 2027
Zone IV bottom-line target₹250 cr to ₹350 cr in first 18 months
New long-term contract revenue potential~₹1,500 cr, 10+ year agreement; commercial operations targeted for FY29
Working capital days55 to 60 days, optimized level
Portfolio on pass-through basisMore than 2/3rd